Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), a clinical stage innovative drug development company focused on developing innovative therapies for immune and ...

Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated ...

Novel small molecule inhibitors show promising efficacy in endometrial cancer, with ongoing trials expanding treatment ...

Plant City, Florida - January 09, 2026 - PRESSADVANTAGE - WhiteSands Alcohol & Drug Rehab Plant City has published ...

A new study published in the journal Science Signaling has found that an immune system protein plays a central role in the ...

This could be a big boost for crop production. Researchers make incredible breakthrough in fight against looming threat to ...

SAN FRANCISCO -- Almost 80% of patients with heavily pretreated advanced/metastatic pancreatic cancer achieved disease ...

Enanta Pharmaceuticals Inc. has announced a new immunology program and updated progress in its immunology pipeline. The company’s new program is focused on developing oral MRGPRX2 inhibitors for type ...

As of Friday, January 09, Rigel Pharmaceuticals, Inc.’s RIGL share price has dipped by 5.01%, which has investors questioning ...

Genentech's PD-L1 inhibitor combined with Avastin and chemo improved median progression-free survival by around 20 months ...

Parabilis Medicines raised $305 million in a Series F round led by RA Capital, Fidelity and Janus Henderson, with crossover ...

“The VA/DoD CPG provides primary care clinicians with up-to-date practical recommendations for accurately staging CKD, predicting progression to kidney failure, and using pharmacotherapies to prevent ...